D. N. Louis, The 2007 WHO Classification of Tumours of the Central Nervous System, Acta Neuropathol. (Berl.), vol.114, issue.2, pp.97-109, 2007.

V. Rigau, French Brain Tumor DataBase: 5-Year Histological Results on 25 756 Cases: FBTDB of Histological Results, Brain Pathol, vol.21, issue.6, pp.633-644, 2004.

T. A. Dolecek, J. M. Propp, N. E. Stroup, and C. Kruchko, CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States, Neuro-Oncol, vol.14, issue.5, pp.1-49, 2005.

H. Loiseau, A. Huchet, and I. Baldi, Épidémiologie des tumeurs cérébrales primitives, Neurologie.com, issue.4, pp.83-86, 2010.

D. Ricard, A. Idbaih, F. Ducray, M. Lahutte, K. Hoang-xuan et al., Primary brain tumours in adults, The Lancet, vol.379, issue.9830, pp.1984-1996, 2012.

I. Baldi, Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period, Neuro-Oncol, vol.13, issue.12, pp.1370-1378, 2000.

E. Ron, Tumors of the Brain and Nervous System after Radiotherapy in Childhood, N. Engl. J. Med, vol.319, issue.16, pp.1033-1039, 1988.

S. K. Singh, I. D. Clarke, T. Hide, and P. B. Dirks, Cancer stem cells in nervous system tumors, Oncogene, vol.23, issue.43, pp.7267-7273, 2004.

A. I. Persson, Non-Stem Cell Origin for Oligodendroglioma, Cancer Cell, vol.18, issue.6, pp.669-682, 2010.

C. D. Stiles and D. H. Rowitch, Glioma Stem Cells: A Midterm Exam, Neuron, vol.58, issue.6, pp.832-846, 2008.

D. W. Parsons, An Integrated Genomic Analysis of Human Glioblastoma Multiforme, Science, vol.321, issue.5897, pp.1807-1812, 2008.

S. Nobusawa, T. Watanabe, P. Kleihues, and H. Ohgaki, IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas, Clin. Cancer Res, vol.15, issue.19, pp.6002-6007, 2009.

S. W. Coons, P. C. Johnson, B. W. Scheithauer, A. J. Yates, and D. K. Pearl, Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas, Cancer, vol.79, issue.7, pp.1381-1393, 1997.

R. J. Jackson, Limitations of stereotactic biopsy in the initial management of gliomas, Neuro-Oncol, vol.3, issue.3, pp.193-200, 2001.

D. N. Louis, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol. (Berl.), vol.131, issue.6, pp.803-820, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01479018

J. C. Buckner, Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma, N. Engl. J. Med, vol.374, issue.14, pp.1344-1355, 2016.

M. J. Van-den and . Bent, Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.31, issue.3, pp.344-350, 2013.

G. Cairncross, Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.31, issue.3, pp.337-343, 2013.

M. J. Van-den and . Bent, Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q nonco-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study, Lancet Lond. Engl, vol.390, issue.10103, pp.1645-1653, 2017.

R. Stupp, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N. Engl. J. Med, vol.352, issue.10, pp.987-996, 2005.

R. Stupp, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, vol.10, issue.5, pp.459-466, 2009.

M. E. Hegi, MGMT gene silencing and benefit from temozolomide in glioblastoma, N. Engl. J. Med, vol.352, issue.10, pp.997-1003, 2005.

J. R. Perry, Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma, N. Engl. J. Med, vol.376, issue.11, p.2017

P. Y. Wen, Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group, J. Clin. Oncol, vol.28, issue.11, pp.1963-1972, 2010.

A. Patsouris, Diagnostic différentiel entre récidive tumorale et radionécrose après radiothérapie stéréotaxique d'une métastase cérébrale, Cancer/Radiothérapie, vol.18, issue.2, pp.142-146, 2014.

M. A. Dufour, Impact de la TEP à la 18F-DOPA sur la décision thérapeutique en RCP lors du diagnostic différentiel entre radionécrose et récidive de néoplasie cérébrale, Médecine Nucl, vol.38, issue.3, pp.132-133, 2014.

M. Chamberlain, E. Rhun, and S. Taillibert, The future of high-grade glioma: Where we are and where are we going, Surg. Neurol. Int, vol.6, issue.2, p.9, 2015.

J. J. Vredenburgh, Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme, J. Clin. Oncol, vol.25, issue.30, pp.4722-4729, 2007.

M. R. Gilbert, A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma, N. Engl. J. Med, vol.370, issue.8, pp.699-708, 2014.

A. D. Norden, Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence, Neurology, vol.70, issue.10, pp.779-787, 2008.

K. E. Wallner, J. H. Galicich, G. Krol, E. Arbit, and M. G. Malkin, Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma, Int. J. Radiat. Oncol. Biol. Phys, vol.16, issue.6, pp.1405-1409, 1989.

C. Barney, G. Shukla, D. Bhamidipati, and J. D. Palmer, Re-irradiation for recurrent glioblastoma multiforme, Chin. Clin. Oncol, vol.6, issue.4, pp.36-36, 2017.

D. N. Antoni, H. Burckel, É. Josset, G. Noël, and F. Mornex, Radiobiologie des doses ablatives en radiothérapie stéréotaxique : mise au point des données récentes, Cancer/Radiothérapie, vol.18, issue.4, pp.264-269, 2014.

A. R. Cabrera, Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline, Pract. Radiat. Oncol, vol.6, issue.4, pp.217-225, 2016.

E. P. Sulman, Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.35, issue.3, pp.361-369, 2017.

J. K. Park, Scale to Predict Survival After Surgery for Recurrent Glioblastoma Multiforme, J. Clin. Oncol, vol.28, issue.24, pp.3838-3843, 2010.

G. Noël and J. Mazeron, Réirradiation cérébrale des tumeurs primitives malignes ou secondaires, Cancer/Radiothérapie, vol.14, issue.6-7, pp.421-437, 2010.

M. Shanker, B. Chua, C. Bettington, M. C. Foote, and M. B. Pinkham, Re-irradiation for recurrent high-grade gliomas: a systematic review and analysis of treatment technique with respect to survival and risk of radionecrosis, Neuro-Oncol. Pract, vol.6, issue.2, pp.144-155, 2019.

A. Prelaj, Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature, Mol. Clin. Oncol, 2018.

K. Ogura, T. Mizowaki, Y. Arakawa, K. Sakanaka, S. Miyamoto et al., Efficacy of salvage stereotactic radiotherapy for recurrent glioma: impact of tumor morphology and method of target delineation on local control, Cancer Med, vol.2, issue.6, pp.942-949, 2013.

E. Fokas, U. Wacker, M. W. Gross, M. Henzel, E. Encheva et al., Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy?, Strahlenther. Onkol. Organ Dtsch. Rontgengesellschaft Al, vol.185, issue.4, pp.235-240, 2009.

A. L. Ho and R. Jena, Re-irradiation in the Brain: Primary Gliomas, Clin. Oncol, vol.30, issue.2, pp.124-136, 2018.

K. H. Cho, W. A. Hall, B. J. Gerbi, P. D. Higgins, W. A. Mcguire et al., Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas, Int. J. Radiat. Oncol. Biol. Phys, vol.45, issue.5, pp.1133-1141, 1999.

P. Navarria, Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO), J. Neurooncol, vol.142, issue.1, pp.59-67, 2019.

A. J. Ulm, W. A. Friedman, P. Bradshaw, K. D. Foote, and F. J. Bova, Radiosurgery in the treatment of malignant gliomas: the University of Florida experience, Neurosurgery, vol.57, issue.3, pp.512-517, 2005.

A. L. Grosu, Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy, Int. J. Radiat. Oncol, vol.63, issue.2, pp.511-519, 2005.

G. Minniti, Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma, J. Neurooncol, vol.103, issue.3, pp.683-691, 2011.

G. Minniti, Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas, J. Neurooncol, vol.111, issue.2, pp.187-194, 2013.

S. E. Combs, Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas, J. Neurooncol, vol.89, issue.2, pp.205-210, 2008.

A. Conti, Efficacy and toxicity of CyberKnife re-irradiation and 'dose dense' temozolomide for recurrent gliomas, Acta Neurochir. (Wien), vol.154, issue.2, pp.203-209, 2012.

M. Flieger, Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option, J. Neurooncol, vol.117, issue.2, pp.337-345, 2014.

L. Q. Shapiro, Patterns of Failure After Concurrent Bevacizumab and Hypofractionated Stereotactic Radiation Therapy for Recurrent High-Grade Glioma, Int. J. Radiat. Oncol, vol.85, issue.3, pp.636-642, 2013.

T. Hundsberger, D. Brügge, P. M. Putora, P. Weder, J. Weber et al., Reirradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas, J. Neurooncol, vol.112, issue.1, pp.133-139, 2013.

D. A. Larson, Gamma knife for glioma: selection factors and survival, Int. J. Radiat. Oncol. Biol. Phys, vol.36, issue.5, pp.1045-1053, 1996.

S. E. Combs, C. Thilmann, L. Edler, J. Debus, and D. Schulz-ertner, Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.23, issue.34, pp.8863-8869, 2005.

S. E. Combs, Moving Second Courses of Radiotherapy Forward: Early Re-Irradiation After Surgical Resection for Recurrent Gliomas Improves Efficacy With Excellent Tolerability, Neurosurgery, 2018.

C. Straube, Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma -the GlioCave study (NOA 17 -ARO 2016/3 -DKTK ROG trial), BMC Cancer, vol.18, issue.1, 2018.

R. S. Hudes, A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma, Int. J. Radiat. Oncol. Biol. Phys, vol.43, issue.2, pp.293-298, 1999.

D. Vordermark, O. Kölbl, K. Ruprecht, G. H. Vince, K. Bratengeier et al., Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma, BMC Cancer, vol.5, p.55, 2005.

S. E. Fogh, Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.28, issue.18, pp.3048-3053, 2010.

S. F. Shepherd, Hypofractionated stereotactic radiotherapy in the management of recurrent glioma, Int. J. Radiat. Oncol. Biol. Phys, vol.37, issue.2, pp.393-398, 1997.

T. Veninga, Reirradiation of primary brain tumours: survival, clinical response and prognostic factors, Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol, vol.59, issue.2, pp.127-137, 2001.

S. E. Combs, L. Edler, R. Rausch, T. Welzel, W. Wick et al., Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma, Acta Oncol. Stockh. Swed, vol.52, issue.1, pp.147-152, 2013.

M. Niyazi, Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis, Radiother. Oncol, vol.127, issue.1, pp.121-127, 2018.

K. Müller, External validation of a prognostic model estimating the survival of patients with recurrent high-grade gliomas after reirradiation, Pract. Radiat. Oncol, vol.5, issue.3, pp.143-150, 2015.

S. E. Combs, Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK), Cancer Med, vol.7, issue.5, pp.1742-1749, 2018.

C. Daumas-duport, S. Blond, . Cl, G. Vedrenne, and . Szikla, Radiolesion versus Recurrence: Bioptic Data in 39 Gliomas After Interstitial, or Combined Interstitial and External Radiation Treatment, Advances in Stereotactic and Functional, pp.291-299, 1984.

A. Ernst-stecken, O. Ganslandt, U. Lambrecht, R. Sauer, and G. Grabenbauer, Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma, J. Neurooncol, vol.81, issue.3, pp.287-294, 2007.